Literature DB >> 9672166

Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients.

K Ikeda1, S Saitoh, Y Suzuki, M Kobayashi, A Tsubota, I Koida, Y Arase, M Fukuda, K Chayama, N Murashima, H Kumada.   

Abstract

BACKGROUND/AIMS/
METHODS: The aim of this study was to elucidate the rate of development to cirrhosis and the rate of appearance of hepatocellular carcinoma in chronic viral hepatitis and to assess the risk factors for the development of disease in 2215 consecutive patients with viral hepatitis who were prospectively studied for a median observation period of 4.1 years.
RESULTS: The rates of development to cirrhosis were 7.6%, 21.7%, and 32.2%, at the 5th, 10th, and 15th year, respectively. The carcinogenesis rates were 3.4%, 10.5%, and 22.4% at the 5th, 10th, and 15th year, respectively. The appearance rates of cancer in 645 patients with only hepatitis B surface antigen and in 1500 patients with only anti-hepatitis C virus antibodies were 2.1% and 4.8% at the 5th year, 4.9% and 13.6% at the 10th year, and 18.8% and 26.0% at the 15th year, respectively. The proportional hazard model identified that the amount of alcohol intake (p= 0.0002) and the indocyanine green retention rate (p= 0.022) were independently associated with carcinogenesis in hepatitis type B; and stage of hepatitis (p<0.0001), gamma-glutamyl transpeptidase (p= 0.0046), history of blood transfusion (p=0.0093), albumin (p=0.012), and amount of alcohol intake (p= 0.031) were independently associated with the carcinogenesis rate in hepatitis type C. Although the severity of portal fibrosis was closely correlated with the future disease development and carcinogenesis in chronic hepatitis C, it was not a good predictor in chronic hepatitis B.
CONCLUSION: These epidemiological results suggest that there are some differences in the activity and modes of disease progression and cancer promotion between hepatitis B virus infection and hepatitis C virus infection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9672166     DOI: 10.1016/s0168-8278(98)80339-5

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  85 in total

1.  Interferon inhibits progression of liver fibrosis and reduces the risk of hepatocarcinogenesis in patients with chronic hepatitis C: a retrospective multicenter analysis of 652 patients.

Authors:  Mitsuhiro Takimoto; Shogo Ohkoshi; Takafumi Ichida; Yasuo Takeda; Minoru Nomoto; Hitoshi Asakura; Akira Naito; Shigeki Mori; Kojiro Hata; Kentaro Igarashi; Hidenori Hara; Hironobu Ohta; Kenji Soga; Toshiaki Watanabe; Tomoteru Kamimura
Journal:  Dig Dis Sci       Date:  2002-01       Impact factor: 3.199

2.  Cost-effectiveness analysis of prophylactic lamivudine use in preventing vertical transmission of hepatitis B virus infection.

Authors:  Hui-Fang Hung; Hsiu-Hsi Chen
Journal:  Pharmacoeconomics       Date:  2011-12       Impact factor: 4.981

3.  Management of chronic hepatitis C and prevention of hepatocellular carcinoma.

Authors:  Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2002       Impact factor: 7.527

4.  A new index for non-invasive assessment of liver fibrosis.

Authors:  Naohiro Ichino; Keisuke Osakabe; Toru Nishikawa; Hiroko Sugiyama; Miho Kato; Shiho Kitahara; Senju Hashimoto; Naoto Kawabe; Masao Harata; Yoshifumi Nitta; Michihito Murao; Takuji Nakano; Yuko Arima; Hiroaki Shimazaki; Koji Suzuki; Kentaro Yoshioka
Journal:  World J Gastroenterol       Date:  2010-10-14       Impact factor: 5.742

5.  Efficacy of interferon monotherapy in young adult patients with chronic hepatitis C virus infection.

Authors:  Kiminori Uka; Fumitaka Suzuki; Norio Akuta; Hitomi Sezaki; Yoshiyuki Suzuki; Tetsuya Hosaka; Takashi Someya; Masahiro Kobayashi; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Hiromitsu Kumada
Journal:  J Gastroenterol       Date:  2006-05       Impact factor: 7.527

Review 6.  Epidemiology of viral hepatitis and hepatocellular carcinoma.

Authors:  Hashem B El-Serag
Journal:  Gastroenterology       Date:  2012-05       Impact factor: 22.682

7.  Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications.

Authors:  L Benvegnù; M Gios; S Boccato; A Alberti
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

8.  Association of γ-glutamyl transferase (GGT) activity with treatment and clinical outcomes in chronic hepatitis C (HCV).

Authors:  James E Everhart; Elizabeth C Wright
Journal:  Hepatology       Date:  2013-04-05       Impact factor: 17.425

9.  Steatosis, liver injury, and hepatocarcinogenesis in hepatitis C viral infection.

Authors:  Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2009-01-16       Impact factor: 7.527

10.  Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin.

Authors:  Eisuke Murakami; Michio Imamura; C Nelson Hayes; Hiromi Abe; Nobuhiko Hiraga; Yoji Honda; Atsushi Ono; Keiichi Kosaka; Tomokazu Kawaoka; Masataka Tsuge; Hiroshi Aikata; Shoichi Takahashi; Daiki Miki; Hidenori Ochi; Hirotaka Matsui; Akinori Kanai; Toshiya Inaba; Fiona McPhee; Kazuaki Chayama
Journal:  Antimicrob Agents Chemother       Date:  2014-01-27       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.